Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer

[1]  N. Harbeck,et al.  Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer , 2010, Breast Cancer Research and Treatment.

[2]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  U. Jeschke,et al.  Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[4]  G. Hortobagyi,et al.  Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Sotiriou,et al.  Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[7]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[8]  D. Larsimont,et al.  Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? , 2008, European journal of cancer.

[9]  P. Sánchez‐Rovira,et al.  Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[10]  A. Goldhirsch,et al.  Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. , 2008, Breast.

[11]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Luini,et al.  Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Robin L. Jones,et al.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.

[14]  Selin Carkaci,et al.  Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.

[15]  R. Neumann,et al.  The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. , 2007, American journal of clinical pathology.

[16]  J. A. van der Hage,et al.  Preoperative chemotherapy for women with operable breast cancer. , 2007, The Cochrane database of systematic reviews.

[17]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[18]  M. Espié,et al.  Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen , 2007, PLoS medicine.

[19]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[20]  A. Ashworth,et al.  Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.

[21]  M. J. van de Vijver,et al.  Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. , 2006, European journal of cancer.

[22]  D. Huntsman,et al.  Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Musolino,et al.  Evaluation of HER-2/Neu Amplification and Other Biological Markers as Predictors of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Primary Breast Cancer: The Role of Anthracycline Dose Intensity , 2006, American journal of clinical oncology.

[24]  J. Robertson,et al.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.

[25]  J. Benítez,et al.  Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas , 2006, Clinical Cancer Research.

[26]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Ang,et al.  Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy , 2005, Cancer.

[28]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[29]  D. Larsimont,et al.  HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel , 2004, Breast Cancer Research and Treatment.

[30]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[31]  J. Albanell,et al.  Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based Chemotherapy , 2004, Oncology.

[32]  C. Sotiriou,et al.  Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. , 2004, Molecular cancer therapeutics.

[33]  M. Piccart,et al.  The best use of chemotherapy in the adjuvant setting. , 2003, Breast.

[34]  Young Suk Park,et al.  Measuring response in solid tumors: comparison of RECIST and WHO response criteria. , 2003, Japanese journal of clinical oncology.

[35]  S. Pinder,et al.  Loss of CD59 expression in breast tumours correlates with poor survival , 2003, The Journal of pathology.

[36]  J. Coindre,et al.  DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer , 2003, British Journal of Cancer.

[37]  Sehwan Han,et al.  Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. , 2003, European journal of cancer.

[38]  M. J. van de Vijver,et al.  Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.

[39]  D. Larsimont,et al.  HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Goldhirsch,et al.  Prediction of response to primary chemotherapy for operable breast cancer. , 1999, European journal of cancer.

[42]  P. Hurteloup,et al.  Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .